|
Tempest Therapeutics, Inc. (TPST): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Tempest Therapeutics, Inc. (TPST) Bundle
In the cutting-edge world of precision oncology, Tempest Therapeutics emerges as a pioneering biotech company transforming cancer treatment through innovative molecular targeting strategies. By developing groundbreaking therapies like TPST-1495 and TPST-1120, this South San Francisco-based enterprise is pushing the boundaries of personalized cancer care, offering hope to patients through advanced scientific research and strategic drug development. Their focused approach on liver cancer and solid tumor treatments represents a critical evolution in targeted therapeutic interventions, promising potentially revolutionary breakthroughs in how we understand and combat complex malignancies.
Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Product
Precision Oncology Therapeutics
Tempest Therapeutics focuses on developing targeted cancer therapies with specific molecular approaches.
| Product | Type | Target | Development Stage |
|---|---|---|---|
| TPST-1495 | Oral small molecule | Multiple cancer pathways | Preclinical/Phase 1 |
| TPST-1120 | Immunotherapy | Tumor microenvironment | Phase 1/2 |
Key Product Characteristics
- Concentration on liver cancer treatments
- Targeting solid tumor therapies
- Personalized cancer care approach
Pipeline Focus Areas
Tempest Therapeutics' product portfolio emphasizes precision medicine with molecular-targeted interventions.
| Treatment Area | Specific Cancer Type | Therapeutic Approach |
|---|---|---|
| Liver Cancer | Hepatocellular Carcinoma | Targeted molecular therapy |
| Solid Tumors | Multiple Cancer Types | Pathway-specific intervention |
Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Place
Headquarters Location
Located at 7000 Shoreline Court, Suite 275, South San Francisco, California 94080.
Research and Development Facilities
| Location | Facility Type | Research Focus |
|---|---|---|
| San Francisco Bay Area | Primary R&D Center | Oncology Drug Development |
Clinical Trial Distribution
Clinical Trial Locations:
- Multiple U.S. research centers across 12 states
- Approximately 25-30 active clinical trial sites
Market Targeting
| Geographic Market | Market Strategy | Primary Focus |
|---|---|---|
| North America | Direct pharmaceutical market penetration | Oncology therapeutics |
Distribution Channels
- Specialized oncology treatment centers
- Hospital pharmacies
- Specialty pharmaceutical distributors
Global Expansion Strategy
Potential International Markets:
- European Union pharmaceutical markets
- Select Asia-Pacific oncology treatment regions
Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Promotion
Scientific Conference Presentations
As of 2024, Tempest Therapeutics participated in the following key oncology conferences:
| Conference | Date | Presentations |
|---|---|---|
| American Association for Cancer Research (AACR) | January 2024 | 2 research presentations |
| American Society of Clinical Oncology (ASCO) | June 2024 | 3 clinical trial data presentations |
Investor Relations Communications
Quarterly earnings reports for 2024 included:
- Q1 2024 earnings call on April 15, 2024
- Total investor communication events: 4 quarterly calls
- Investor presentation deck updates: 3 times in 2024
Digital Marketing Strategy
Digital marketing channels utilized in 2024:
| Channel | Reach | Engagement Rate |
|---|---|---|
| LinkedIn Professional Network | 12,500 oncology professionals | 3.7% |
| Targeted Medical Research Websites | 8,200 researchers | 2.9% |
Collaboration Announcements
Partnerships and collaborations in 2024:
- Academic partnerships: 2 new collaborations
- Pharmaceutical industry partnerships: 1 strategic alliance
- Research collaboration value: $3.2 million
Biotech Investment Community Engagement
Investment community interactions in 2024:
| Event Type | Number of Events | Total Participants |
|---|---|---|
| Investor Conferences | 4 | 350 institutional investors |
| Biotech Analyst Meetings | 6 | 125 financial analysts |
Tempest Therapeutics, Inc. (TPST) - Marketing Mix: Price
Financial Overview
As of Q4 2023, Tempest Therapeutics reported:
- Cash and cash equivalents: $13.3 million
- Net loss: $24.9 million for the fiscal year 2023
- Research and development expenses: $18.5 million
Pricing Strategy Considerations
Current financial positioning indicates a pre-revenue biotechnology model with pricing strategy dependent on future drug development outcomes.
| Financial Metric | Amount | Year |
|---|---|---|
| Total Operating Expenses | $37.4 million | 2023 |
| Research Investment | $18.5 million | 2023 |
| Cash Runway | Estimated 9-12 months | 2024 |
Investment and Funding
Funding sources include:
- Venture capital investments
- Public market financing
- Total raised capital: $89.6 million
Potential Pricing Factors
Key pricing determinants for future therapeutic products:
- Clinical trial success rates
- FDA approval probability
- Comparative market treatment costs
- Potential insurance reimbursement models
Market Positioning Metrics
| Product Category | Estimated Market Value | Potential Pricing Range |
|---|---|---|
| Oncology Therapeutics | $150-$250 million | $50,000 - $150,000 per treatment course |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.